Parameter
| Biomarker | Deletion of CDKN2A/p16 | Full name | Cyclin-dependent kinase inhibitor 2A deletion | Molecular Type | Nucleic acid (DNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Subtype identification, prognostic evaluation | ||
| Disease | Disease Pancreatic Cancer | Disease Subtypes | / | ||
| Organ | Pancreatic ductal adenocarcinoma (PDAC) | Test Sample / Technology Platform | Organization (next-generation sequencing, immunohistochemical) | ||
| Pathobiological Mechanisms | CDKN2A gene deletion leads to loss of p16 protein expression, lift its regulation of cell cycle, promoting tumor cell proliferation, associated with invasive tumor | ||||
| Clinical Availability Status | Clinical research phase: used to identify aggressive subtype, assess the risk of disease progression | ||||
| Notes and Dynamics | 30% to 40% of patients with PDAC is missing, is a key driver events of PDAC, lack of tumor in patients with malignant degree is higher | ||||